Company profile
ADAGENE INC.
NASDAQ:ADAGBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ADG-106 | phase1_2 | — | 4 | completed, terminated |
| FIRASTOTUG | phase1 | — | 3 | completed, terminated |
| MUZASTOTUG | phase1 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04501276 | phase1 | completed | 2020-09-23 | 2024-01-17 | Adagene Inc | A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients |
| NCT05277402 | phase1 | completed | 2022-02-09 | 2022-08-01 | Adagene Inc | ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| NCT05405595 | phase1_2 | recruiting | 2022-06-15 | 2026-10-31 | Adagene Inc | ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors |
| NCT04645069 | phase1_2 | completed | 2021-03-15 | 2024-01-29 | Adagene Inc | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors |
| NCT04775680 | phase1_2 | terminated | 2021-03-11 | 2023-02-09 | Adagene (Suzhou) Limited | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma |
FDA applications (0)
No records yet.